Not available
Quote | Neurocrine Biosciences Inc. (NASDAQ:NBIX)
Last: | $137.92 |
---|---|
Change Percent: | 0.0% |
Open: | $137.83 |
Close: | $137.92 |
High: | $138.72 |
Low: | $135.97 |
Volume: | 1,228,874 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
News | Neurocrine Biosciences Inc. (NASDAQ:NBIX)
2024-03-28 09:06:17 ET “Biotech industry has found its footing again”, says Karen Andersen – a Morningstar strategist. Here are the top U.S. based stocks within this space that are particularly worth owning for 2024. Vertex Pharmaceuticals Inc (NASDAQ: VRTX) ...
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults PR Newswire SAN DIEGO , March 28, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), tod...
Message Board Posts | Neurocrine Biosciences Inc. (NASDAQ:NBIX)
Subject | By | Source | When |
---|---|---|---|
https://finance.yahoo.com/m/ac97a7cc-59a6-39e8-8438-16d26de87a27/voyager%2C-neur | TheFinalCD | investorshub | 01/09/2023 7:23:31 PM |
whytestocks: $NBIX News Article - Neurocrine Biosciences Reports Third Quarter 2022 Financial Result | whytestocks | investorshangout | 11/01/2022 3:55:56 PM |
whytestocks: $NBIX News Article - Neurocrine Biosciences Presents INGREZZA (valbenazine) Data on Sus | whytestocks | investorshangout | 09/19/2022 12:45:51 PM |
whytestocks: $NBIX News Article - Neurocrine Biosciences to Present Study Findings on Evolving Tardi | whytestocks | investorshangout | 09/15/2022 7:35:48 PM |
whytestocks: $NBIX News Article - Neurocrine Biosciences to Present New INGREZZA (valbenazine) and O | whytestocks | investorshangout | 09/10/2021 7:05:49 PM |
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
2024-03-28 09:06:17 ET “Biotech industry has found its footing again”, says Karen Andersen – a Morningstar strategist. Here are the top U.S. based stocks within this space that are particularly worth owning for 2024. Vertex Pharmaceuticals Inc (NASDAQ: VRTX) ...
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults PR Newswire SAN DIEGO , March 28, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), tod...
H.C. Wainwright initiated coverage on Voyager Therapeutics Inc (NASDAQ:VYGR), noting a growing franchise of novel, highly-differenti...